Aru Narendran

Calgary, AB, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications

Editorial Expression of Concern: Tumour exosome integrins determine organotropic metastasis.

Editorial Expression of Concern: Tumour exosome integrins determine organotropic metastasis.

Journal: Nature
Published: August 05, 2026

PV-10 enhances immune responses in hepatitis B vaccination through STING pathway.

PV-10 enhances immune responses in hepatitis B vaccination through STING pathway.

Journal: Human vaccines & immunotherapeutics
Published: October 07, 2025

Gene alterations in inborn errors of immunity and their presence in cancers: Implications for oncogenesis, progression, and outcomes.

Gene alterations in inborn errors of immunity and their presence in cancers: Implications for oncogenesis, progression, and outcomes.

Journal: Human immunology
Published: August 20, 2025

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.

Journal: Cancers
Published: July 31, 2025

Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study.

Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study.

Journal: Targeted oncology
Published: July 04, 2025

Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma.

Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma.

Journal: Scientific reports
Published: May 05, 2025

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.

Journal: Blood neoplasia
Published: July 29, 2024

Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10.

Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10.

Journal: Cancers
Published: March 05, 2024

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma.

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma.

Journal: Blood neoplasia
Published: February 20, 2024

Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.

Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.

Journal: Biomedicines
Published: December 22, 2023

Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT).

Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT).

Journal: Neuro-oncology practice
Published: July 17, 2023

The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia.

The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia.

Journal: Genes
Published: July 13, 2023
Showing 1-12 of 80

Last Updated: 09/26/2026